| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6185502 | Gynecologic Oncology | 2013 | 6 Pages |
Abstract
The addition of 3-AP to cisplatin radiochemotherapy was tolerable and produced high rates of clinical and metabolic responses in women with cervical and vaginal cancers. Future randomized phase II and III clinical trials of 3-AP radiochemotherapy are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Charles A. Kunos, Tomas Radivoyevitch, Steven Waggoner, Robert Debernardo, Kristine Zanotti, Kimberly Resnick, Nancy Fusco, Ramon Adams, Raymond Redline, Peter Faulhaber, Afshin Dowlati,